Sangamo Therapeutics Launches Auction for Clinical-Stage Neuropathic Pain Program
FROM THE WIRE · FINANCE.YAHOO.COM
Sangamo Therapeutics, Inc. Auction process initiated for ST-503 program for chronic neuropathic pain, expected to be completed in fourth quarter of 2026 Previously announced asset sale transactions with PTC and Lilly have closed, generating $163.55 million in gross cash proceeds…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralSangamo initiates auction for ST-503 chronic neuropathic pain program after completing prior asset sales.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Auction process initiated for ST-503 clinical-stage chronic neuropathic pain program.
- 02Expected completion in Q4 2026.
- 03Prior asset sales to PTC and Lilly generated $163.55 million in gross proceeds.
- 04Seven sites activated in Phase 1/2 STAND study evaluating safety and efficacy.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Sangamo Therapeutics, Inc.0.1401 USDMarket closedtoday -6.60%Neutral Eli Lilly and Company1,166.51 USDMarket closedtoday -1.36%Neutral PTC Inc.193.96 USDMarket closedtoday -0.22%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets